Another interesting observation in our cohort is that breast cancers with PTEN mutations were more likely to be HER2-negative, while no significant differences between patients with/without PTEN mutations in terms of age, ER status, PR status, tumor size, lymph node metastasis, and Ki67 score. This evidence concerns the gene MKI67 and breast carcinoma.